查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971124

鐮狀細胞疾病市場分析及預測（至2035年）：依類型、產品類型、服務、技術、應用、設備、流程、最終使用者、功能分類

Sickle Cell Disease Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Device, Process, End User, Functionality
出版日期: | 出版商: Global Insight Services | 英文 357 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

鐮狀細胞疾病市場預計將從2024年的49億美元成長到2034年的207億美元，複合年成長率約為15.5%。鐮狀細胞疾病市場涵蓋旨在管理和治療鐮狀細胞貧血症（一種遺傳性血液疾病）的治療方案和服務。該市場包括藥品、基因療法和輔助護理產品。公眾意識的提高、基因編輯技術的進步以及醫療保健投資的增加正在推動市場成長。主要企業正致力於研發能夠改善患者預後和生活品質的創新治療方法。

在治療方法進步和公眾意識不斷提高的推動下，鐮狀細胞疾病市場正經歷顯著成長。其中，藥物治療領域成長最為迅猛，這主要得益於基因療法和CRISPR技術的進步，因為它們具有根治性細胞疾病的潛力。羥基脲和L-麩醯胺酸療法仍是重要的治療方法，有助於緩解症狀，提升患者的生活品質。診斷領域成長位居第二，主要得益於早期檢測和非侵入性檢測技術的創新。就地檢驗設備日益普及，使得及時介入和管理成為可能。對個人化醫療的日益重視進一步推動了對客製化治療方案的需求。生物製藥領域的研發投入正在加速成長，以滿足未被滿足的需求並改善治療效果。遠端醫療和行動醫療應用等數位健康工具的整合，透過提供遠端監測和支持，正在改變患者照護。這些進步為鐮狀細胞疾病領域帶來了盈利機會。

市場區隔
類型 鐮狀細胞貧血、鐮狀BETA地中海貧血、鐮狀血紅蛋白C疾病
產品 藥品、輸血製品、基因治療產品、止痛藥、羥基脲、L-麩醯胺酸、沃克洛托、克里扎利珠單抗
服務 病患諮詢、遺傳諮詢、診斷服務、遠端醫療
科技 基因編輯、CRISPR、 RNA干擾、幹細胞療法
應用領域 疾病管理、調查、診斷和治療
醫療設備 診斷和監測設備
過程 輸血和骨髓移植
最終用戶 醫院、專科診所、研究機構、製藥公司
功能 疼痛管理、貧血管理、器官損傷預防

市場概況：

鐮狀細胞疾病市場正經歷顯著的變革，新型療法的推出和創新治療方法的湧現對市場佔有率產生了重大影響。先進產品的上市承諾能夠提高療效並改善患者預後，這導致了日益激烈的定價競爭。製藥公司正大力投資研發，以期為市場帶來新的解決方案，進而改變競爭格局。這種動態環境正在推動快速發展，並為相關人員提供豐厚的機會。在競爭標竿分析方面，主要參與者正透過策略聯盟和收購來鞏固其市場地位，從而實現差異化競爭。監管的影響至關重要，北美和歐洲嚴格的核准流程影響市場的准入和擴張。該市場的特點是臨床試驗投入巨大，並且越來越重視個人化醫療。這些因素，加上法規結構，正在塑造鐮狀細胞疾病市場的發展軌跡，並為分析和策略規劃提供全面的環境。

主要趨勢和促進因素：

鐮狀細胞疾病 (SCD) 市場正經歷變革性成長，這主要得益於基因療法和個人化醫療的進步。關鍵趨勢包括基於 CRISPR 技術的治療方法開發以及對根治性治療的日益重視。這些創新旨在解決 SCD 的根本病因，並有望提供超越症狀緩解的長期解決方案。製藥公司正大力投資研發，以期將這些最先進治療推向市場。另一個促進因素是人們對 SCD 的認知和診斷水平的提高，尤其是在高發生率地區。這種認知的提高正在推動早期療育和疾病管理的改善。此外，政府和非營利組織也在發揮關鍵作用，他們資助研究並支持患者獲得新興療法。遠端醫療和數位健康平台也帶來了新的機遇，這些平台能夠增強病患監測和參與度。隨著這些技術的不斷發展，SCD 市場有望實現患者預後改善和醫療服務效率提升。

限制與挑戰：

鐮狀細胞疾病市場面臨許多顯著的限制和挑戰。其中一個主要限制因素是新型治療方法的高成本，這限制了低收入地區病患的就醫途徑。許多醫療系統難以負擔這些費用，導致治療資源分配不均。此外，某些地區對鐮狀細胞疾病的認知和教育不足，阻礙了早期診斷和介入。臨床試驗的複雜性也為市場帶來挑戰。臨床試驗參與者的招募和保留十分困難，影響了新治療方法的研發。此外，缺乏接受過鐮狀細胞疾病管理訓練的醫護人員也影響了患者的治療效果。新型療法的核准流程通常漫長而昂貴，監管障礙也構成挑戰。最後，社會和經濟因素（例如，社會歧視和污名化）進一步加劇了患者獲得醫療服務的困難。所有這些挑戰共同阻礙了鐮狀細胞疾病治療市場的發展。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 鐮狀細胞貧血症
    • 鐮狀細胞BETA-地中海貧血
    • 鐮狀血紅素C疾病
  • 市場規模及預測：依產品分類
    • 製藥
    • 輸血製品
    • 基因治療產品
    • 疼痛管理藥物
    • 羥基脲
    • L-麩醯胺酸
    • 體素
    • 克里扎利珠單抗
  • 市場規模及預測：依服務分類
    • 患者諮詢
    • 遺傳諮詢
    • 診斷服務
    • 遠端醫療
  • 市場規模及預測：依技術分類
    • 基因編輯
    • CRISPR
    • RNA干擾
    • 幹細胞療法
  • 市場規模及預測：依應用領域分類
    • 疾病管理
    • 調查
    • 診斷
    • 治療
  • 市場規模及預測：依設備分類
    • 診斷設備
    • 監控設備
  • 市場規模及預測：依製程分類
    • 輸血
    • 骨髓移植
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 專科診所
    • 研究所
    • 製藥公司
  • 市場規模及預測：依功能分類
    • 疼痛管理
    • 貧血管理
    • 預防器官損傷

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Global Blood Therapeutics
  • Emmaus Life Sciences
  • Agios Pharmaceuticals
  • Novartis Gene Therapies
  • Bluebird Bio
  • Sangamo Therapeutics
  • CRISPR Therapeutics
  • Editas Medicine
  • Graphite Bio
  • Beam Therapeutics
  • Imara Inc
  • Protagonist Therapeutics
  • Fate Therapeutics
  • ArcherDX
  • Rocket Pharmaceuticals

第9章：關於我們

簡介目錄
Product Code: GIS34251

Sickle Cell Disease Market is anticipated to expand from $4.9 billion in 2024 to $20.7 billion by 2034, growing at a CAGR of approximately 15.5%. The Sickle Cell Disease Market encompasses therapeutic solutions and services aimed at managing and treating sickle cell anemia, a genetic blood disorder. This market includes pharmaceuticals, gene therapies, and supportive care products. Increasing awareness, advancements in gene editing technologies, and rising healthcare investments are propelling market growth. Key players focus on innovative treatments to improve patient outcomes and quality of life.

The Sickle Cell Disease Market is experiencing significant growth, fueled by advancements in treatment options and increased awareness. The pharmaceutical segment is the top performer, with gene therapy and CRISPR technology leading due to their potential to offer curative solutions. Hydroxyurea and L-glutamine therapies remain critical, providing symptomatic relief and improving patient quality of life. The diagnostics segment is the second-highest performer, driven by innovations in early detection and non-invasive testing techniques. Point-of-care testing devices are gaining popularity, facilitating timely intervention and management. The growing emphasis on personalized medicine further boosts the demand for tailored therapeutic approaches. Biopharmaceutical investments in R&D are accelerating, aiming to address unmet needs and enhance treatment efficacy. The integration of digital health tools, such as telemedicine and mobile health applications, is transforming patient care, offering remote monitoring and support. These advancements collectively promise lucrative opportunities within the sickle cell disease landscape.

Market Segmentation
TypeSickle Cell Anemia, Sickle Beta Thalassemia, Sickle Hemoglobin-C Disease
ProductPharmaceuticals, Blood Transfusion Products, Gene Therapy Products, Pain Management Drugs, Hydroxyurea, L-Glutamine, Voxelotor, Crizanlizumab
ServicesPatient Counseling, Genetic Counseling, Diagnostic Services, Telemedicine
TechnologyGene Editing, CRISPR, RNA Interference, Stem Cell Therapy
ApplicationDisease Management, Research, Diagnosis, Treatment
DeviceDiagnostic Devices, Monitoring Devices
ProcessBlood Transfusion, Bone Marrow Transplantation
End UserHospitals, Specialty Clinics, Research Institutes, Pharmaceutical Companies
FunctionalityPain Management, Anemia Management, Organ Damage Prevention

Market Snapshot:

The Sickle Cell Disease Market is witnessing significant shifts, with market share being influenced by the introduction of novel therapeutics and innovative treatment modalities. Pricing strategies are becoming increasingly competitive, driven by the launch of advanced products that promise enhanced efficacy and patient outcomes. Pharmaceutical companies are actively investing in research and development to bring new solutions to the market, thereby altering the competitive landscape. This dynamic environment is fostering rapid advancements and offering lucrative opportunities for stakeholders. In terms of competition benchmarking, key players are differentiating themselves through strategic collaborations and acquisitions to bolster their market positions. Regulatory influences play a pivotal role, with stringent approval processes in North America and Europe impacting market entry and expansion. The market is characterized by robust investment in clinical trials and a growing emphasis on personalized medicine. These factors, combined with regulatory frameworks, are shaping the trajectory of the Sickle Cell Disease Market, offering a comprehensive landscape for analysis and strategic planning.

Geographical Overview:

The Sickle Cell Disease market is witnessing varied growth patterns across global regions. North America remains at the forefront, driven by advanced healthcare infrastructure and substantial research funding. The presence of leading pharmaceutical companies enhances market dynamics, fostering innovation in treatment options. Europe follows, with a strong emphasis on research collaborations and governmental support for rare disease management. This region benefits from a robust regulatory framework that accelerates drug approvals. In Asia Pacific, the market is expanding swiftly due to increasing awareness and improving healthcare access. Countries like India and China are emerging as key growth pockets, driven by large patient populations and rising investments in healthcare. Latin America is also gaining momentum, with Brazil and Mexico investing in healthcare reforms to address sickle cell disease. Meanwhile, the Middle East & Africa are recognizing the importance of tackling genetic disorders, with countries like Nigeria and South Africa prioritizing healthcare initiatives and research funding.

Key Trends and Drivers:

The Sickle Cell Disease (SCD) market is experiencing transformative growth driven by advancements in gene therapy and personalized medicine. Key trends include the development of CRISPR-based treatments and the increasing focus on curative therapies. These innovations promise to address the root cause of SCD, offering long-term solutions beyond symptomatic relief. Pharmaceutical companies are investing heavily in research and development to bring these cutting-edge therapies to market. Another driver is the growing awareness and diagnosis of SCD, particularly in regions with high prevalence. This awareness is leading to earlier interventions and better management of the disease. Additionally, government and non-profit organizations are playing a crucial role by funding research and supporting patient access to emerging treatments. Opportunities are also emerging in telemedicine and digital health platforms, which are enhancing patient monitoring and engagement. As these technologies evolve, they are expected to improve patient outcomes and streamline healthcare delivery in the SCD market.

Restraints and Challenges:

The Sickle Cell Disease market encounters several prominent restraints and challenges. A significant restraint is the high cost of novel therapies, which limits accessibility for patients in low-income regions. Many healthcare systems struggle to absorb these costs, leading to disparities in treatment availability. Furthermore, the lack of awareness and education about sickle cell disease in certain areas hampers early diagnosis and intervention. The market also faces challenges due to the complexity of clinical trials. Recruiting and retaining participants for trials is difficult, impacting the development of new therapies. Additionally, there is a shortage of healthcare professionals trained in managing sickle cell disease, which affects patient outcomes. Regulatory hurdles also pose a challenge, as navigating the approval process for new treatments is often time-consuming and costly. Lastly, socio-economic factors, such as stigma and discrimination, further complicate patient access to care. These challenges collectively impede progress in the sickle cell disease market.

Key Players:

Global Blood Therapeutics, Emmaus Life Sciences, Agios Pharmaceuticals, Novartis Gene Therapies, Bluebird Bio, Sangamo Therapeutics, CRISPR Therapeutics, Editas Medicine, Graphite Bio, Beam Therapeutics, Imara Inc, Protagonist Therapeutics, Fate Therapeutics, ArcherDX, Rocket Pharmaceuticals

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Device
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by End User
  • 2.9 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Sickle Cell Anemia
    • 4.1.2 Sickle Beta Thalassemia
    • 4.1.3 Sickle Hemoglobin-C Disease
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Pharmaceuticals
    • 4.2.2 Blood Transfusion Products
    • 4.2.3 Gene Therapy Products
    • 4.2.4 Pain Management Drugs
    • 4.2.5 Hydroxyurea
    • 4.2.6 L-Glutamine
    • 4.2.7 Voxelotor
    • 4.2.8 Crizanlizumab
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Patient Counseling
    • 4.3.2 Genetic Counseling
    • 4.3.3 Diagnostic Services
    • 4.3.4 Telemedicine
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Gene Editing
    • 4.4.2 CRISPR
    • 4.4.3 RNA Interference
    • 4.4.4 Stem Cell Therapy
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Disease Management
    • 4.5.2 Research
    • 4.5.3 Diagnosis
    • 4.5.4 Treatment
  • 4.6 Market Size & Forecast by Device (2020-2035)
    • 4.6.1 Diagnostic Devices
    • 4.6.2 Monitoring Devices
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Blood Transfusion
    • 4.7.2 Bone Marrow Transplantation
  • 4.8 Market Size & Forecast by End User (2020-2035)
    • 4.8.1 Hospitals
    • 4.8.2 Specialty Clinics
    • 4.8.3 Research Institutes
    • 4.8.4 Pharmaceutical Companies
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Pain Management
    • 4.9.2 Anemia Management
    • 4.9.3 Organ Damage Prevention

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 Device
      • 5.2.1.7 Process
      • 5.2.1.8 End User
      • 5.2.1.9 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 Device
      • 5.2.2.7 Process
      • 5.2.2.8 End User
      • 5.2.2.9 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 Device
      • 5.2.3.7 Process
      • 5.2.3.8 End User
      • 5.2.3.9 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 Device
      • 5.3.1.7 Process
      • 5.3.1.8 End User
      • 5.3.1.9 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 Device
      • 5.3.2.7 Process
      • 5.3.2.8 End User
      • 5.3.2.9 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 Device
      • 5.3.3.7 Process
      • 5.3.3.8 End User
      • 5.3.3.9 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 Device
      • 5.4.1.7 Process
      • 5.4.1.8 End User
      • 5.4.1.9 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 Device
      • 5.4.2.7 Process
      • 5.4.2.8 End User
      • 5.4.2.9 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 Device
      • 5.4.3.7 Process
      • 5.4.3.8 End User
      • 5.4.3.9 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 Device
      • 5.4.4.7 Process
      • 5.4.4.8 End User
      • 5.4.4.9 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 Device
      • 5.4.5.7 Process
      • 5.4.5.8 End User
      • 5.4.5.9 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 Device
      • 5.4.6.7 Process
      • 5.4.6.8 End User
      • 5.4.6.9 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 Device
      • 5.4.7.7 Process
      • 5.4.7.8 End User
      • 5.4.7.9 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 Device
      • 5.5.1.7 Process
      • 5.5.1.8 End User
      • 5.5.1.9 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 Device
      • 5.5.2.7 Process
      • 5.5.2.8 End User
      • 5.5.2.9 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 Device
      • 5.5.3.7 Process
      • 5.5.3.8 End User
      • 5.5.3.9 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 Device
      • 5.5.4.7 Process
      • 5.5.4.8 End User
      • 5.5.4.9 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 Device
      • 5.5.5.7 Process
      • 5.5.5.8 End User
      • 5.5.5.9 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 Device
      • 5.5.6.7 Process
      • 5.5.6.8 End User
      • 5.5.6.9 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 Device
      • 5.6.1.7 Process
      • 5.6.1.8 End User
      • 5.6.1.9 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 Device
      • 5.6.2.7 Process
      • 5.6.2.8 End User
      • 5.6.2.9 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 Device
      • 5.6.3.7 Process
      • 5.6.3.8 End User
      • 5.6.3.9 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 Device
      • 5.6.4.7 Process
      • 5.6.4.8 End User
      • 5.6.4.9 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 Device
      • 5.6.5.7 Process
      • 5.6.5.8 End User
      • 5.6.5.9 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Global Blood Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Emmaus Life Sciences
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Agios Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Novartis Gene Therapies
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Bluebird Bio
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Sangamo Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 CRISPR Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Editas Medicine
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Graphite Bio
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Beam Therapeutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Imara Inc
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Protagonist Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Fate Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 ArcherDX
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Rocket Pharmaceuticals
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us